Global Plasma Fractionation Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: Precision business insights
Veröffentlicht am: 09.02.2018 12:14
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Global Plasma Fractionation Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Pressekontakt:

Human plasma contains the large variety of proteins, however, only a few of these proteins are help in producing therapeutic plasma products. Plasma is used in prevention and treatment of various life threatening diseases caused by trauma, immunologic disorders, and infections. Plasma fractionation process is majorly used in treating protein deficiency condition in healthcare applications. The proteins extracted from the plasma are majorly categorized into three main classes: immunoglobulins which are useful in treatment of autoimmune disorders and increasing the immune response of the body, clotting factors which are help in treatment of blood disorders such as haemophilia, and the albumins which are useful in conditions of decreased albumin levels or during fluid loss. Plasma fractionation process is carried by different criteria such as solubility of the products, and their physical and chemical conditions such as ionic strengths, pH levels, and temperature, etc. The removal or inactivation of viruses and prions is an important function of plasma fractionation, and it can be carried by various mechanical and physical treatments for virus inactivation such as nano filtration, detergent/solvent treatment, heat treatment, chromatography centrifugation, ultrafiltration, and sterile filtration in order to achieve homogeneity of plasma, and reduce the risks of viral transmissions.

Plasma fractionation market expected to grow at significant rate over the forecast period due to rise in the incidence of immune and bleeding disorders, increase in the use of alpha-1 antitrypsin and immunoglobulin, rise in prevalence of Alpha-1 Antitrypsin Deficiency (AATD), emphysema, and haemophilia. In addition, development in plasma techniques and plasma utilization are the key factors expected to boost the plasma fractionation market. However, high cost for the plasma products, adverse effects associated with the plasma fractionation products, lack of reimbursement policies, stringent regulatory policies, and increase in the recombinant coagulation factors might hinder the growth of plasma fractionation market over the forecast timeframe.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/#ulp-4H8Z4LpNMLEuOnnx


Global plasma fractionation market segmented based on the product type, application, and end user

Based on product type, global plasma fractionation market segmented into the following:
• Albumin
• Immunoglobulin
o Intravenous immunoglobulin
o Subcutaneous immunoglobulin
o Others
• Coagulation factor concentrates
o Factor viii
o Factor ix
o Factor xiii
o Prothrombin complex concentrates
o Von Willebrand factor (VWF)
• Protease inhibitors
• Other plasma fractionation products

Based on application, global plasma fractionation market segmented into the following:
• Neurology
• Haematology
• Immunology
• Rheumatology
• Haemato-oncology
• Critical Care
• Pulmonology
• Others

Based on end-user, global plasma fractionation market segmented into the following:
• Hospitals
• Clinics
• Academic Institutes
• Clinical Research Laboratories


To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/#ulp-c654SbFYO64MsOhu


Several international players are actively involved in the development of global plasma fractionation products. In 2015, immunoglobulins commanded for the largest share of the global plasma fractionation market due to rise in prevalence and incidence autoimmune disorders (according to International Journal of Celiac Disease, 2015 the world prevalence and incidence of Autoimmune Diseases are increasing, the global net percent increased per year prevalence and incidence of autoimmune disorders were 12.5±7.9 and 19.1±43.1 respectively). However, the protease inhibitors are expected to highest growth in the forecasting period, due to increasing use of proteases for respiratory diseases and growing application in various diseases. Partnerships, agreements, new products launch, collaborations, acquisitions and mergers, joint ventures, are being adopted by various key players in the global plasma fractionation market. For instance, in 2003, Probitas Pharma acquired Alpha Therapeutic from Mitsubishi Pharma, similarly, Octapharma acquired Mexican fractionator Probifasa S.A. de C.V. for developing the plasma products.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/#ulp-14mlyhjMGhVjZqa3


Geographically, global plasma fractionation market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global plasma fractionation market followed by Europe and Asia-Pacific. The largest share of North-America in global plasma fractionation market is due to increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for chronic diseases in this region (According to Centres of Disease Control (CDC), in 2012, chronic diseases were one of the leading causes of death and disability in the U.S., with an estimated 117 Mn adults suffering from some form of chronic disease). Europe is the second largest region for global plasma fractionation market due to the rise in aging population and increase in the prevalence of chronic diseases. However, Asia-Pacific is expected to register significant growth rate over the forecast owing to the increasing aging population, growing using of albumin and immunoglobulin, and an increasing focus on better diagnosis, prophylactic treatments, medical research, and organ transplantations in Asia-Pacific regions.

Some of the players in plasma fractionation market are Grifols S.A (Spain), CSL Ltd. (Australia), Shire (Ireland), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (OGEL GmbH) (Germany), LFB S.A (France), and Sanquin (Netherlands) to name a few.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com



Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.